06 Dec Eylea As Good As Lucentis
The FDA approved Eylea as a new treatment for wet macular degeneration. Recent reports indicate the drug is similar to Lucentis after the initial year of treatment. Why is this bad news?...
The FDA approved Eylea as a new treatment for wet macular degeneration. Recent reports indicate the drug is similar to Lucentis after the initial year of treatment. Why is this bad news?...
Alimera Sciences suffers set back with Iluvien. In a complete response letter to the company, the FDA did not approve the device for diabetic retinopathy citing concerns over safety....
The American Academy of Ophthalmology starts this week. I will be going to learn about the latest in retinal disease, but also will be teaching...
The FDA issued an alert that 12 cases of intraocular infection were linked to Avastin. The infections; however, were linked to a single pharmacy and, perhaps, dirty syringes....
VEGF Trap Eye is another anti-VEGF medication to be injected into the eye for the treatment of wet macular degeneration. The FDA did not approve recently, but will reconsider by November!...
Though the FDA upheld its decision no longer approve Avastin for the treatment of breast cancer. The drug is still available for eye patients....
VEGF-Trap (aka aflibercept), another anti-VEGF drug, moves closer to FDA approval as it received "priority review" status. This status means that the FDA process will be accelerated and the drug can be reviewed in 6 months versus the usual 10 month period....
Diabetic macular edema occurs in virtually every patient with diabetes. It is the most common "complication" of diabetic retinopathy. Treatment is safe, painless and effective....
Iluvien, a promising sustained drug delivery system for the treatment of diabetic macular edema, fails to pass FDA scrutiny...
Retinal specialists have been using intravitreal injections to treat retinal disease. Sustained release systems are gaining in popularity. Soon, more than retinal disease will be treated with these devices....